• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.

作者信息

Kimmich Christoph R, Terzer Tobias, Benner Axel, Hansen Timon, Carpinteiro Alexander, Dittrich Tobias, Veelken Kaya, Jauch Anna, Huhn Stefanie, Basset Marco, Goldschmidt Hartmut, Müller-Tidow Carsten, Schönland Stefan O, Hegenbart Ute

机构信息

Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3.

DOI:10.1002/ajh.26191
PMID:33844864
Abstract
摘要

相似文献

1
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.达雷妥尤单抗、来那度胺和地塞米松治疗系统性轻链淀粉样变性：疗效高、毒性相关及1q21获得的主要不良反应
Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3.
2
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
3
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
4
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.达雷妥尤单抗联合硼替佐米及地塞米松治疗新诊断的2004版梅奥分期IIIA或IIIB期轻链型淀粉样变性的疗效与安全性：一项前瞻性II期研究
Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.
5
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.真实世界研究达雷妥尤单抗联合方案治疗初诊轻链（AL）淀粉样变性患者。
Hematol Oncol. 2024 Jul;42(4):e3289. doi: 10.1002/hon.3289.
6
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.来那度胺、伊沙佐米联合地塞米松治疗复发型轻链淀粉样变性。
Br J Haematol. 2020 May;189(4):643-649. doi: 10.1111/bjh.16401. Epub 2020 Jan 26.
7
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于复发多发性骨髓瘤的1/2期研究。
Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.
8
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.来那度胺和地塞米松治疗复发性/难治性免疫球蛋白轻链（AL）淀粉样变性：一项随访时间长的大样本患者的研究结果。
Br J Haematol. 2021 Oct;195(2):230-243. doi: 10.1111/bjh.17685. Epub 2021 Aug 3.
9
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.达雷妥尤单抗治疗免疫球蛋白轻链淀粉样变性。
N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.
10
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).维奈克拉联合达雷妥尤单抗可使一名患有t(11;14)的AL淀粉样变性患者出现血液学完全缓解及器官反应。
Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22.

引用本文的文献

1
The molecular landscape of AL amyloidosis.AL淀粉样变性的分子图谱。
Br J Haematol. 2025 May;206(5):1297-1311. doi: 10.1111/bjh.20070. Epub 2025 Apr 11.
2
Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival.系统性轻链淀粉样变性中1q21的获得或扩增与梅奥分期晚期、浆细胞疾病及更差的总生存期相关。
Ann Hematol. 2025 Mar;104(3):1777-1788. doi: 10.1007/s00277-025-06256-7. Epub 2025 Mar 22.
3
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.
肾AL型淀粉样变性：诊断、分期及管理的最新进展
J Clin Med. 2024 Mar 18;13(6):1744. doi: 10.3390/jcm13061744.
4
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.皮下注射达雷妥尤单抗治疗系统性AL淀粉样变性的安全性和有效性
Ther Clin Risk Manag. 2023 Dec 28;19:1063-1074. doi: 10.2147/TCRM.S325859. eCollection 2023.
5
Diagnosis and Treatment of AL Amyloidosis.诊断与治疗 AL 型淀粉样变。
Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18.
6
Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.基于达雷妥尤单抗静脉注射治疗 AL 淀粉样变性的疗效和安全性：一项系统评价和荟萃分析。
Cancer Cell Int. 2022 Jul 4;22(1):222. doi: 10.1186/s12935-022-02635-6.
7
Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.分析伴有显性心脏或肾脏受累的 AL 淀粉样变性患者的完整 lambda 轻链胚系使用情况。
PLoS One. 2022 Feb 25;17(2):e0264407. doi: 10.1371/journal.pone.0264407. eCollection 2022.
8
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.免疫球蛋白轻链淀粉样变性的遗传发病机制：基本特征及临床应用
Exp Hematol Oncol. 2021 Jul 20;10(1):43. doi: 10.1186/s40164-021-00236-z.